New Issue: Orbital Catastrophe Ahead? Read Now

U.S. Regulators Test Organs-on-Chips for Food-Safety Monitoring

The goal is to compare these engineered livers with animal models, with an eye toward replacing animal testing

Join Our Community of Science Lovers!

The US Food and Drug Administration (FDA) has started testing whether livers-on-a-chip—miniature models of human organs engineered to mimic biological functions—can reliably model human reactions to food and food-borne illnesses. The experiments will help the agency to determine whether companies can substitute chip data for animal data when applying for the approval of a new compound, such as a food additive, that could prove toxic. It is the first time that a regulatory agency anywhere in the world has pursued organs-on-chips as an alternative to animal testing.

Suzanne Fitzpatrick, senior adviser for toxicology in the food-safety division of the FDA, announced the move on April 11 in a blog post. Although the chips were designed for testing drugs, Fitzpatrick’s division wants to use them to see how individual organs process products such as dietary supplements and cosmetics. They will also be able to test how food-borne pathogens affect specific organs. FDA food-safety scientists will first evaluate the human-liver chip, before moving on to kidney, lung and intestine models.

The chips are made by Emulate, a biotechnology company in Boston, Massachusetts. The miniature organs contain multiple types of human liver cells grown on a scaffold, and continuously pump a blood-like fluid through the system to deliver nutrients and remove waste. Emulate chief executive Geraldine Hamilton says that they can also add immune system components to the chip to test how it affects liver metabolism.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


A long way to go

“I'm excited that people are willing to try this new technology out,” says Lawrence Vernetti, a toxicologist at the University of Pittsburgh in Pennsylvania, who is developing a different kind of liver-on-a-chip. Some aspects of animal metabolism are markedly different from humans: chocolate, for instance, is toxic to dogs. Although animals are usually good models for predicting toxicity issues in humans, he says, they are not fool-proof. If the long-term goal is to reduce the number of animals used for testing, “we have to come up with a system where regulators in science will trust the answers that will come out of it”, Vernetti says.

Vernetti says that he is surprised by how quickly regulators have begun testing the devices, but he says that the decision is timely because of increasing pressure from the public to minimize the use of animals in research. In 2013, for instance, the European Union banned the sale of cosmetics that have been tested on animals. “You just can’t stop testing these things—you have to give an alternative,” Vernetti says. “These human-on-chip devices might be a nice answer.”

The announcement is a victory for animal-rights activists. “Animals don’t have to suffer through poisoning tests to improve health care for humans, and we’re thrilled that the FDA is taking action,” says Kathy Guillermo, senior vice-president of People for the Ethical Treatment of Animals (PETA) in Norfolk, Virginia, in a statement to Nature.

Still, it will be some time before organs-on-chips replace animal testing entirely. Hamilton points out that even if the human-liver chip processes a toxin without incident, there could be unforeseen effects on other organs, such as the heart. Although researchers are working towards ways to link as many as ten chips together, eliminating animal research entirely “is not in our sights right now”, Hamilton says. “We have a lot to do between now and then.”

This article is reproduced with permission and was first published on April 12, 2017.

Sara Reardon is a freelance biomedical journalist based in Bozeman, Mont. She is a former staff reporter at Nature, New Scientist and Science and has a master’s degree in molecular biology.

More by Sara Reardon

First published in 1869, Nature is the world's leading multidisciplinary science journal. Nature publishes the finest peer-reviewed research that drives ground-breaking discovery, and is read by thought-leaders and decision-makers around the world.

More by Nature magazine

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe